Literature DB >> 6212905

Radioactive excretion in human milk following administration of technetium Tc 99m macroaggregated albumin.

W B Pittard, R Merkatz, B D Fletcher.   

Abstract

Albumin-tagged sodium pertechnetate (technetium) is routinely used in nuclear medicine for scanning procedures of the lung. The rate of excretion of this radionuclide into breast milk and the resultant potential radiation hazard to the nursing infant have received little attention. Therefore the milk from a nursing mother who required a lung scan because of suspected pulmonary emboli using an intravenous injection of 4 mCi of technetium Tc 99 macroaggregated human serum albumin was monitored. Albumin tagging severely limited the entrance of technetium into her milk and the radioactivity of the milk returned to base line by 24 hours. A total of 2.02 muCi of technetium was measured in the 24-hour milk collection after technetium injection and 94% of this amount was excreted by 15.5 hours. This amount of technetium administered orally to a newborn would deliver a total body radiation dose of .3 mrad. Therefore, an infant would receive trivial doses of radiation if breast-feeding were resumed 15.5 hours after administration of the radionuclide to the mother and nursing can clearly be resumed safely 24 hours after injection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212905

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Nuclear medicine and the nursing mother.

Authors:  A J Coakley; P J Mountford
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-20

2.  Excretion of technetium 99m hexakismethoxyisobutylisonitrile in milk.

Authors:  S M Rubow; A Ellmann; J le Roux; J Klopper
Journal:  Eur J Nucl Med       Date:  1991

3.  Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption.

Authors:  Sigrid Leide-Svegborn; Lars Ahlgren; Lennart Johansson; Sören Mattsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-06       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.